Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023
The transdermal drug delivery systems market is projected to grow at a CAGR of 4.5% during the forecast period.
The transdermal drug delivery systems market is expected to reach 7.1 billion by 2023 from an estimated USD 5.7 billion in 2018, at a CAGR of 4.5% during the forecast period. Market growth is largely driven by the global increase in the prevalence of chronic diseases. In addition, technological advancements in transdermal drug delivery systems are expected to support market growth in the coming years. However, drug failures and recalls of transdermal drug delivery systems are expected to restrain market growth to a certain extent.
By application, the pain management segment is expected to grow at the highest rate during the forecast period.
On the basis of application, the transdermal drug delivery systems market is segmented into five broad categories—pain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications (smoking cessation, motion sickness, and overactive bladder treatment). The pain management segment is expected to grow at the highest CAGR during the forecast period owing to the high burden of chronic pain worldwide and the growing availability of transdermal products for pain management.
The transdermal patches segment is expected to dominate the market in 2018.
On the basis of type, the transdermal drug delivery systems market is segmented into transdermal patches and transdermal semisolids. In 2018, the transdermal patches segment is expected to account for a dominant share of the transdermal drug delivery systems market. This drug delivery system offers several advantages, such as reduced dosing frequency, improved bioavailability, reduced adverse events, and drug input termination at any point by the removal of the patch. Also, the use of patches results in increased patient compliance due to their non-invasive nature and painless application. These factors are expected to drive market growth.
The North American transdermal drug delivery systems market is expected to grow at the highest CAGR during the forecast period.
North America, comprising the US and Canada, offers high-growth opportunities for players in the transdermal drug delivery systems market. This segment is slated to register the highest CAGR during the forecast period. Some of the factors driving market growth in the North American region are rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.
Break of primary participants was as mentioned below:
Research Coverage:
The report analyzes the transdermal drug delivery systems market and aims at estimating the market size and future growth potential of this market based on various segments such as applications, type, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.
This report provides insights into the following pointers:
The transdermal drug delivery systems market is expected to reach 7.1 billion by 2023 from an estimated USD 5.7 billion in 2018, at a CAGR of 4.5% during the forecast period. Market growth is largely driven by the global increase in the prevalence of chronic diseases. In addition, technological advancements in transdermal drug delivery systems are expected to support market growth in the coming years. However, drug failures and recalls of transdermal drug delivery systems are expected to restrain market growth to a certain extent.
By application, the pain management segment is expected to grow at the highest rate during the forecast period.
On the basis of application, the transdermal drug delivery systems market is segmented into five broad categories—pain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications (smoking cessation, motion sickness, and overactive bladder treatment). The pain management segment is expected to grow at the highest CAGR during the forecast period owing to the high burden of chronic pain worldwide and the growing availability of transdermal products for pain management.
The transdermal patches segment is expected to dominate the market in 2018.
On the basis of type, the transdermal drug delivery systems market is segmented into transdermal patches and transdermal semisolids. In 2018, the transdermal patches segment is expected to account for a dominant share of the transdermal drug delivery systems market. This drug delivery system offers several advantages, such as reduced dosing frequency, improved bioavailability, reduced adverse events, and drug input termination at any point by the removal of the patch. Also, the use of patches results in increased patient compliance due to their non-invasive nature and painless application. These factors are expected to drive market growth.
The North American transdermal drug delivery systems market is expected to grow at the highest CAGR during the forecast period.
North America, comprising the US and Canada, offers high-growth opportunities for players in the transdermal drug delivery systems market. This segment is slated to register the highest CAGR during the forecast period. Some of the factors driving market growth in the North American region are rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.
Break of primary participants was as mentioned below:
- By Company Type – Tier 1–55%, Tier 2–25% and Tier 3–20%
- By Designation – C-level–43%, Director Level–32%, Others–25%
- By Region – North America–38%, Europe–29%, Asia Pacific–23%, RoW–10%
Research Coverage:
The report analyzes the transdermal drug delivery systems market and aims at estimating the market size and future growth potential of this market based on various segments such as applications, type, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.
This report provides insights into the following pointers:
- Market Penetration: Comprehensive information on the services offered by the top players in the transdermal drug delivery systems market. The report analyzes the market based on applications, type, end user, and region
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the transdermal drug delivery systems market
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various transdermal drug delivery systems solutions across regions
- Market Diversification: Exhaustive information about solutions and services, untapped regions, recent developments, and investments in the transdermal drug delivery systems market
- Competitive Assessment: In-depth assessment of market shares, strategies, distribution networks, and manufacturing capabilities of the leading players in the market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key Data from Secondary Sources
2.1.2 PRIMARY DATA
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Key Industry Insights
2.2 MARKET SIZE ESTIMATION
2.2.1 MARKET DATA VALIDATION AND TRIANGULATION
2.3 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET OVERVIEW
4.2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018
4.3 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018
4.4 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: GEOGRAPHIC SNAPSHOT
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of chronic diseases
5.2.1.2 Technological advancements in transdermal drug delivery systems
5.2.2 RESTRAINTS
5.2.2.1 Drug failure and recalls of transdermal drug delivery systems
5.2.3 OPPORTUNITIES
5.2.3.1 Collaborations between pharmaceutical companies and drug delivery firms
5.2.3.2 Self-administration and home care drug delivery systems
5.2.4 CHALLENGES
5.2.4.1 Technical barriers related to skin irritation and permeability
6 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE
6.1 INTRODUCTION
6.2 TRANSDERMAL PATCHES
6.2.1 DRUG-IN-ADHESIVE PATCHES
6.2.2 MATRIX PATCHES
6.2.3 RESERVOIR MEMBRANE PATCHES
6.2.4 MICRONEEDLE PATCHES
6.3 TRANSDERMAL SEMISOLIDS
6.3.1 GELS
6.3.2 OINTMENTS
6.3.3 SPRAYS
7 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 PAIN MANAGEMENT
7.2.1 PAIN MANAGEMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET
7.3 HORMONAL APPLICATIONS
7.3.1 TESTOSTERONE REPLACEMENT THERAPY
7.3.1.1 Skin irritation, poor absorption of drugs, high costs, and the need for frequent dosing are factors limiting market growth
7.3.2 TRANSDERMAL ESTROGEN THERAPY
7.3.2.1 Growing use of transdermal contraceptive patches is likely to drive the market for transdermal estrogen therapy
7.4 CENTRAL NERVOUS SYSTEM DISORDERS
7.4.1 INCREASING INCIDENCE OF PARKINSON’S AND ALZHEIMER’S DISEASE TO DRIVE THE MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS
7.5 CARDIOVASCULAR DISEASES
7.5.1 AVAILABILITY OF ALTERNATIVE AND ADVANCED DRUG DELIVERY OPTIONS TO LIMIT MARKET GROWTH
7.6 OTHER APPLICATIONS
7.6.1 INCREASING DEMAND FOR ADVANCED TRANSDERMAL MICRONEEDLE PATCHES FOR DIABETES MANAGEMENT—A KEY MARKET DRIVER
8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOME CARE SETTINGS
8.3 HOSPITALS & CLINICS
9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 Rising prevalence of targeted disease and development of technologically advanced transdermal drug delivery systems—key factors driving market growth
9.2.2 CANADA
9.2.2.1 Rising prevalence of chronic diseases and funding for the development of transdermal drug delivery systems to drive market growth
9.3 EUROPE
9.3.1 GERMANY
9.3.1.1 Growing focus of pharmaceutical companies in Germany on the development of transdermal products to drive market growth
9.3.2 UK
9.3.2.1 Increasing funding for the R&D of innovative transdermal technologies to drive market growth
9.3.3 FRANCE
9.3.3.1 Development of transdermal drug delivery systems by local players to support market growth
9.3.4 ROE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.1.1 Increasing number of product approvals and growing focus of local players on R&D of transdermal systems to support market growth
9.4.2 CHINA
9.4.2.1 Growing focus of major players in China towards the development of transdermal drug delivery systems to drive market growth
9.4.3 INDIA
9.4.3.1 Growing awareness among healthcare providers and patients and increasing focus on noninvasive methods of drug delivery to drive market growth
9.4.4 ROPAC
9.5 ROW
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 MARKET SHARE ANALYSIS
10.3 MARKET SHARE ANALYSIS, BY APPLICATION
10.3.1 PAIN MANAGEMENT
10.3.2 HORMONAL APPLICATIONS
10.3.3 CENTRAL NERVOUS SYSTEM DISORDERS
10.3.4 CARDIOVASCULAR DISEASES
10.4 COMPETITIVE SCENARIO
10.4.1 PRODUCT LAUNCHES AND APPROVALS
10.4.2 EXPANSIONS
10.4.3 AGREEMENTS AND COLLABORATIONS
10.4.4 ACQUISITIONS
11 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 HISAMITSU PHARMACEUTICAL CO., INC.
11.2 MYLAN N.V.
11.3 UCB S.A.
11.4 NOVARTIS AG
11.5 GLAXOSMITHKLINE PLC
11.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.7 JOHNSON & JOHNSON (J&J)
11.8 ENDO INTERNATIONAL, INC.
11.9 PURDUE PHARMA L.P.
11.10 LAVIPHARM
11.11 LEAD CHEMICALS CO., INC.
11.12 LUYE PHARMA GROUP
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key Data from Secondary Sources
2.1.2 PRIMARY DATA
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Key Industry Insights
2.2 MARKET SIZE ESTIMATION
2.2.1 MARKET DATA VALIDATION AND TRIANGULATION
2.3 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET OVERVIEW
4.2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018
4.3 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018
4.4 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: GEOGRAPHIC SNAPSHOT
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of chronic diseases
5.2.1.2 Technological advancements in transdermal drug delivery systems
5.2.2 RESTRAINTS
5.2.2.1 Drug failure and recalls of transdermal drug delivery systems
5.2.3 OPPORTUNITIES
5.2.3.1 Collaborations between pharmaceutical companies and drug delivery firms
5.2.3.2 Self-administration and home care drug delivery systems
5.2.4 CHALLENGES
5.2.4.1 Technical barriers related to skin irritation and permeability
6 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE
6.1 INTRODUCTION
6.2 TRANSDERMAL PATCHES
6.2.1 DRUG-IN-ADHESIVE PATCHES
6.2.2 MATRIX PATCHES
6.2.3 RESERVOIR MEMBRANE PATCHES
6.2.4 MICRONEEDLE PATCHES
6.3 TRANSDERMAL SEMISOLIDS
6.3.1 GELS
6.3.2 OINTMENTS
6.3.3 SPRAYS
7 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 PAIN MANAGEMENT
7.2.1 PAIN MANAGEMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET
7.3 HORMONAL APPLICATIONS
7.3.1 TESTOSTERONE REPLACEMENT THERAPY
7.3.1.1 Skin irritation, poor absorption of drugs, high costs, and the need for frequent dosing are factors limiting market growth
7.3.2 TRANSDERMAL ESTROGEN THERAPY
7.3.2.1 Growing use of transdermal contraceptive patches is likely to drive the market for transdermal estrogen therapy
7.4 CENTRAL NERVOUS SYSTEM DISORDERS
7.4.1 INCREASING INCIDENCE OF PARKINSON’S AND ALZHEIMER’S DISEASE TO DRIVE THE MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS
7.5 CARDIOVASCULAR DISEASES
7.5.1 AVAILABILITY OF ALTERNATIVE AND ADVANCED DRUG DELIVERY OPTIONS TO LIMIT MARKET GROWTH
7.6 OTHER APPLICATIONS
7.6.1 INCREASING DEMAND FOR ADVANCED TRANSDERMAL MICRONEEDLE PATCHES FOR DIABETES MANAGEMENT—A KEY MARKET DRIVER
8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOME CARE SETTINGS
8.3 HOSPITALS & CLINICS
9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 Rising prevalence of targeted disease and development of technologically advanced transdermal drug delivery systems—key factors driving market growth
9.2.2 CANADA
9.2.2.1 Rising prevalence of chronic diseases and funding for the development of transdermal drug delivery systems to drive market growth
9.3 EUROPE
9.3.1 GERMANY
9.3.1.1 Growing focus of pharmaceutical companies in Germany on the development of transdermal products to drive market growth
9.3.2 UK
9.3.2.1 Increasing funding for the R&D of innovative transdermal technologies to drive market growth
9.3.3 FRANCE
9.3.3.1 Development of transdermal drug delivery systems by local players to support market growth
9.3.4 ROE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.1.1 Increasing number of product approvals and growing focus of local players on R&D of transdermal systems to support market growth
9.4.2 CHINA
9.4.2.1 Growing focus of major players in China towards the development of transdermal drug delivery systems to drive market growth
9.4.3 INDIA
9.4.3.1 Growing awareness among healthcare providers and patients and increasing focus on noninvasive methods of drug delivery to drive market growth
9.4.4 ROPAC
9.5 ROW
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 MARKET SHARE ANALYSIS
10.3 MARKET SHARE ANALYSIS, BY APPLICATION
10.3.1 PAIN MANAGEMENT
10.3.2 HORMONAL APPLICATIONS
10.3.3 CENTRAL NERVOUS SYSTEM DISORDERS
10.3.4 CARDIOVASCULAR DISEASES
10.4 COMPETITIVE SCENARIO
10.4.1 PRODUCT LAUNCHES AND APPROVALS
10.4.2 EXPANSIONS
10.4.3 AGREEMENTS AND COLLABORATIONS
10.4.4 ACQUISITIONS
11 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 HISAMITSU PHARMACEUTICAL CO., INC.
11.2 MYLAN N.V.
11.3 UCB S.A.
11.4 NOVARTIS AG
11.5 GLAXOSMITHKLINE PLC
11.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.7 JOHNSON & JOHNSON (J&J)
11.8 ENDO INTERNATIONAL, INC.
11.9 PURDUE PHARMA L.P.
11.10 LAVIPHARM
11.11 LEAD CHEMICALS CO., INC.
11.12 LUYE PHARMA GROUP
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
LIST OF TABLES
Table 1 COMPARISON BETWEEN TRANSDERMAL PATCHES AND TRANSDERMAL SEMISOLID FORMULATIONS
Table 2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 3 TRANSDERMAL PATCHES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 4 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 5 TRANSDERMAL SEMISOLIDS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 6 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 7 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR PAIN MANAGEMENT
Table 8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2016–2023 (USD MILLION)
Table 9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HORMONAL APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 10 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HORMONAL APPLICATIONS, BY TYPE, 2016–2023 (USD MILLION)
Table 11 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR TESTOSTERONE REPLACEMENT THERAPY
Table 12 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR TRANSDERMAL ESTROGEN THERAPY
Table 13 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR CENTRAL NERVOUS SYSTEM DISORDERS
Table 14 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 15 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR CARDIOVASCULAR DISEASES
Table 16 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 17 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR OTHER APPLICATIONS
Table 18 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 19 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 20 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 21 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 22 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 23 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 24 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 25 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 26 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 27 US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 28 US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 29 US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 30 CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 31 CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 32 CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 33 DEVELOPMENTS IN THE FIELD OF TDDS IN EUROPE, 2015–2018
Table 34 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 35 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 36 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 37 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 38 GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 39 GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 40 GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 41 UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 42 UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 43 UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 44 FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 45 FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 46 FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 47 ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 48 ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 49 ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 50 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 51 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 52 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 53 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 54 JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 55 JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 56 JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 57 CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 58 CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 59 CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 60 INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 61 INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 62 INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 63 ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 64 ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 65 ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 66 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 67 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 68 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 69 PRODUCT LAUNCHES AND APPROVALS
Table 70 EXPANSIONS
Table 71 AGREEMENTS AND COLLABORATIONS
Table 1 COMPARISON BETWEEN TRANSDERMAL PATCHES AND TRANSDERMAL SEMISOLID FORMULATIONS
Table 2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 3 TRANSDERMAL PATCHES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 4 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 5 TRANSDERMAL SEMISOLIDS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 6 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 7 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR PAIN MANAGEMENT
Table 8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2016–2023 (USD MILLION)
Table 9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HORMONAL APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 10 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HORMONAL APPLICATIONS, BY TYPE, 2016–2023 (USD MILLION)
Table 11 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR TESTOSTERONE REPLACEMENT THERAPY
Table 12 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR TRANSDERMAL ESTROGEN THERAPY
Table 13 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR CENTRAL NERVOUS SYSTEM DISORDERS
Table 14 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 15 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR CARDIOVASCULAR DISEASES
Table 16 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 17 TRANSDERMAL DRUG DELIVERY SYSTEMS AVAILABLE FOR OTHER APPLICATIONS
Table 18 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 19 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 20 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 21 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 22 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 23 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 24 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 25 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 26 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 27 US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 28 US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 29 US: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 30 CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 31 CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 32 CANADA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 33 DEVELOPMENTS IN THE FIELD OF TDDS IN EUROPE, 2015–2018
Table 34 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 35 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 36 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 37 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 38 GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 39 GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 40 GERMANY: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 41 UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 42 UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 43 UK: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 44 FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 45 FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 46 FRANCE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 47 ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 48 ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 49 ROE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 50 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 51 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 52 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 53 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 54 JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 55 JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 56 JAPAN: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 57 CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 58 CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 59 CHINA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 60 INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 61 INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 62 INDIA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 63 ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 64 ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 65 ROAPAC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 66 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 67 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 68 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 69 PRODUCT LAUNCHES AND APPROVALS
Table 70 EXPANSIONS
Table 71 AGREEMENTS AND COLLABORATIONS
LIST OF FIGURES
Figure 1 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION
Figure 2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: RESEARCH METHODOLOGY
Figure 3 RESEARCH DESIGN
Figure 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 DATA TRIANGULATION METHODOLOGY
Figure 8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018
Figure 9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2018
Figure 10 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2018
Figure 11 GEOGRAPHIC SNAPSHOT: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET
Figure 12 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS ARE KEY FACTORS DRIVING THE GROWTH OF THE MARKET
Figure 13 TRANSDERMAL PATCHES TO DOMINATE THE TRANSDERMAL DRUG DELIVERY SYSTEMS IN NORTH AMERICAN MARKET DURING THE FORECAST PERIOD
Figure 14 TRANSDERMAL PATCHES TO DOMINATE THE TRANSDERMAL DRUG DELIVERY SYSTEMS IN NORTH EUROPEAN MARKET DURING THE FORECAST PERIOD
Figure 15 JAPAN IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 16 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
Figure 17 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
Figure 18 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION)
Figure 19 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
Figure 20 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2018 VS. 2023
Figure 21 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
Figure 22 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
Figure 23 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
Figure 24 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
Figure 25 KEY DEVELOPMENTS IN THE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET (2015–2018)
Figure 26 MARKET SHARE ANALYSIS BY KEY PLAYERS (2015–2018)
Figure 27 HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT (2017)
Figure 28 MYLAN: COMPANY SNAPSHOT (2017)
Figure 29 UCB: COMPANY SNAPSHOT (2017)
Figure 30 NOVARTIS: COMPANY SNAPSHOT (2017)
Figure 31 GSK: COMPANY SNAPSHOT (2017)
Figure 32 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2017)
Figure 33 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017)
Figure 34 ENDO INTERNATIONAL: COMPANY SNAPSHOT (2017)
Figure 35 LUYE PHARMA: COMPANY SNAPSHOT (2017)
Figure 1 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION
Figure 2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: RESEARCH METHODOLOGY
Figure 3 RESEARCH DESIGN
Figure 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 DATA TRIANGULATION METHODOLOGY
Figure 8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018
Figure 9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2018
Figure 10 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2018
Figure 11 GEOGRAPHIC SNAPSHOT: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET
Figure 12 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS ARE KEY FACTORS DRIVING THE GROWTH OF THE MARKET
Figure 13 TRANSDERMAL PATCHES TO DOMINATE THE TRANSDERMAL DRUG DELIVERY SYSTEMS IN NORTH AMERICAN MARKET DURING THE FORECAST PERIOD
Figure 14 TRANSDERMAL PATCHES TO DOMINATE THE TRANSDERMAL DRUG DELIVERY SYSTEMS IN NORTH EUROPEAN MARKET DURING THE FORECAST PERIOD
Figure 15 JAPAN IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 16 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
Figure 17 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
Figure 18 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION)
Figure 19 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
Figure 20 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2018 VS. 2023
Figure 21 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
Figure 22 EUROPE: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
Figure 23 ASIA PACIFIC: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
Figure 24 ROW: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SNAPSHOT
Figure 25 KEY DEVELOPMENTS IN THE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET (2015–2018)
Figure 26 MARKET SHARE ANALYSIS BY KEY PLAYERS (2015–2018)
Figure 27 HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT (2017)
Figure 28 MYLAN: COMPANY SNAPSHOT (2017)
Figure 29 UCB: COMPANY SNAPSHOT (2017)
Figure 30 NOVARTIS: COMPANY SNAPSHOT (2017)
Figure 31 GSK: COMPANY SNAPSHOT (2017)
Figure 32 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2017)
Figure 33 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017)
Figure 34 ENDO INTERNATIONAL: COMPANY SNAPSHOT (2017)
Figure 35 LUYE PHARMA: COMPANY SNAPSHOT (2017)
